Janux Therapeutics, Inc. (JANX) Stock Analysis

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

Thu, May 7, 2026 at 11:05 PM UTC 3 min read

Janux Therapeutics, Inc. (JANX) reported a loss for Q1, falling short of revenue estimates. This underperformance raises concerns among investors about the company's growth potential and ability to meet market expectations. As the biotech sector remains competitive, investors will be closely monitoring Janux's future developments and strategies to regain momentum.

Read full article →

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

Thu, April 2, 2026 at 6:29 PM UTC 2 min read

Janux Therapeutics has received a $35 million milestone payment from Bristol-Myers Squibb (BMY) as part of their collaboration agreement. This payment is significant as it underscores the progress of Janux's drug development programs, potentially enhancing investor confidence in the company's pipeline and future revenue prospects. The successful partnership with a major pharmaceutical player like BMY may also attract further investment interest in Janux's innovative therapies.

Read full article →